Adaptive Biotechnologies Lands $105,000,000 Series D Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=d322de28-41e8-476b-afa5-d98b0cc41636
Date
4/8/2014
Company Name
Adaptive Biotechnologies
Mailing Address
1551 Eastlake Avenue East Seattle, WA 98102 USA
Company Description
Adaptive Biotechnologies’ platform technology breaks open the field of genomics immunology. T-cell receptor profiling using Adaptive’s proprietary technology and software allows scientists to study the adaptive immune system to an unprecedented depth via high-throughput T-Cell Receptor (TCR) sequencing.
Website
http://www.adaptivebiotech.com
Transaction Type
Venture Equity
Transaction Amount
$105,000,000
Transaction Round
Series D
Proceeds Purposes
This investment will enable the Company to expand globally its preeminent immunosequencing research platform and downstream validated clinical diagnostic products.
M&A Terms
Venture Investor